Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS Evaluation of Gilenya in RRMS
NCT02048072Phase 4Completed
- Start
- Jul 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS). Primary endpoint: Root Mean Square of the Successive Differences at 4.5 hours. Started Jul 2013; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02048072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048072.